(Q43528067)

24 November 2017

A high content screening assay to predict human drug-induced liver injury during drug discovery (English)

1 reference

24 November 2017

0 references

1 reference

Mikael Persson

1

1 reference

24 November 2017

Anni F Løye

series ordinal

2

1 reference

24 November 2017

Tomas Mow

series ordinal

3

1 reference

24 November 2017

Jorrit J Hornberg

series ordinal

4

1 reference

24 November 2017

8 August 2013

1 reference

Journal of Pharmacological and Toxicological Methods

24 November 2017

1 reference

24 November 2017

68

1 reference

24 November 2017

302-313

1 reference

24 November 2017

3

1 reference

Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Trial watch: Phase II failures: 2008-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Phase III and submission failures: 2007–2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Risk factors for idiosyncratic drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Drug-induced mitochondrial toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Functions of autophagy in hepatic and pancreatic physiology and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Strategies to reduce late-stage drug attrition due to mitochondrial toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

The significance of mitochondrial toxicity testing in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Cell based approaches for evaluation of drug-induced liver injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Mechanisms of drug-induced liver injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Idiosyncratic drug hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Drug-induced hepatotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Evaluation of drugs with specific organ toxicities in organ-specific cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

The determination and interpretation of the therapeutic index in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

A high content screening assay for identifying lysosomotropic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Central role of mitochondria in drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Human Anti-Mitochondria Autoantibodies Appearing in Iproniazid-Induced Immunoallergic Hepatitis Recognize Human Liver Monoamine Oxidase B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Current concepts of mechanisms in drug-induced hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

The future of drug safety testing: expanding the view and narrowing the focus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Cellular imaging predictions of clinical drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.08.001

10.1016/J.VASCN.2013.08.001

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference